Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive. RESEARCH DESIGN AND METHODS: To assess the metabolic effects of chronic inhibition of the mTORC1/S6K1 pathway, rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15 days before metabolic phenotyping. RESULTS: Chronic rapamycin treatment reduced adiposity and fat cell number, which was associated with a coordinated downregulation of genes involved in both lipid uptake and output. Rapamycin treatment also promoted insulin resistance, severe glucose intolerance, and increased gluconeogenesis. The latter was associated with elevated expression of hepatic gluconeogenic master genes, PEPCK and G6Pase, and increased expression of the transcriptional coactivator peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) as well as enhanced nuclear recruitment of FoxO1, CRTC2, and CREB. These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop. CONCLUSIONS: These findings unravel a novel mechanism by which mTORC1/S6K1 controls gluconeogenesis through modulation of several key transcriptional factors. The robust induction of the gluconeogenic program in liver of rapamycin-treated rats underlies the development of severe glucose intolerance even in the face of preserved hepatic insulin signaling to Akt and despite a modest reduction in adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, compensatory pathways are activated in response to chronic rapamycin treatment [66, 67].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 3×
“Diabetes 59:1338–1348, 2010 The mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that belongs to the phosphatidylinositol (PI) kinase-related protein kinase family (1).”
BackgroundWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“We also found that rapamycin markedly increases PGC-1 mRNA expression, which likely contributes to the upregulation of the gluconeogenic enzymes, as observed in type 2 diabetes (32).”
BackgroundAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature · doi:10.1038/35093131 · Cited by 1,440 · cited 1×
“CREB may also promote gluconeogenesis through increased PGC-1 expression (43).”
BackgroundGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 1×
“GSK-3 phosphorylation was recently found to be preserved despite complete loss of Akt Ser473 phosphorylation in mouse embryo fibroblasts from rictor knockout animals (49).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 1×
“The mTOR complex 1 (mTORC1) is composed of mTOR, G L, PRAS40, deptor, and raptor and regulates cell growth, whereas the complex 2 (mTORC2) consists of mTOR, G L, protor-1, mSIN1, deptor, and rictor and controls cytoskeleton regulation and cell survival (1,2).”
Background
Research works printed but not linked: 1
- Hamada, Upregulation of the mTOR complex 1 pathway by Rheb in pancreatic β cells leads to increased β cell mass and prevention of hyperglycemia, Diabetes
Cited by
Items 201–300 of 463
Obesity is a common soil for premature cardiac aging and heart diseases - Role of autophagy
Sun, M., Tan, Y., Rexiati, M., Dong, M., & Guo, W. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.004 · Cited by 32
Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age
Duran‐Ortiz, S., List, E. O., Basu, R., & Kopchick, J. J. (2021) · Pituitary · doi:10.1007/s11102-020-01117-0 · Cited by 30
“1 3 rapamycin treatment in rats lads to glucose and ketone body production in the liver, despite improved insulin signaling, as evidenced by increased activation of downstream effectors of the insulin receptor, such as insulin receptor substrate-1 and -2, and Phosphoinositide 3-kinase; while AKT phosphorylation seem t…”
BackgroundGurram, R. K., Kujur, W., Maurya, S. K., & Agrewala, J. N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.545871 · Cited by 30
“Unfortunately, Rapa increases the chance of diabetes (20).”
BackgroundUpstream signalling of mTORC1 and its hyperactivation in type 2 diabetes (T2D)
Ali, M. Z., Bukhari, S. A., Ali, M. Z., & Lee, H.-W. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.12.206 · Cited by 31
“moting insulin resistance and dropping -cell function and mass (91, 92).”
BackgroundShi, Y., Jia, M., Xu, L., Fang, Z., Wu, W., Zhang, Q., Chung, P., Lin, Y., Wang, S., & Zhang, Y. (2019) · Phytotherapy Research · doi:10.1002/ptr.6318 · Cited by 30
“On the basis of prior studies addressing mTOR and FOXO1 in regulating dyslipidemia (Houde et al., 2010; Sajan et al., 2014; Zhong et al., 2017), we hypothesized their major roles played downstream of miR‐96 (Data S6: miR‐96 predicted target score, mTOR: 98, FOXO1: 75, Atg16l1: 81, Atg9a: 55).”
BackgroundGrowth or longevity: the TOR’s decision on lifespan regulation
Wei, Y., Zhang, Y., & Cai, Y. (2013) · Biogerontology · doi:10.1007/s10522-013-9435-6 · Cited by 32
Wang, Q., He, G., Mai, K., Xu, W., Zhou, H., Wang, X., & Mei, L. (2016) · Scientific Reports · doi:10.1038/srep28068 · Cited by 31
Hypertension in malignancy-an underappreciated problem
Małyszko, J., Małyszko, M., Kozłowski, L., Kozlowska, K., & Małyszko, J. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25024 · Cited by 29
Smadja-Lamère, N., Shum, M., Déléris, P., Roux, P. P., Abe, J., & Marette, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.474148 · Cited by 32
“Western Analyses—Western blots were performed as described (23).”
MethodSelf-citationSu, M., Xu, Y., Jiang, X., Huang, M., Zhang, L., Yuan, L., Xu, X.-H., Zhu, Q., Gao, J., Lu, J., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.014 · Cited by 30
A molecular rheostat at the interface of cancer and diabetes
Osman, M. A., Sarkar, F. H., & Rodriguez-Boulan, E. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.04.005 · Cited by 30
“Systemic administration of rapamycin in animals produced results varying from inconsistent insulin levels to hyperglycemia and hypoglycemia [47, 48], and clinical trials of rapamycin or its structurally related analogs “Rapalogs” resulted in hyperlipidemia and glucose intolerance in humans [10, 47, 48].”
BackgroundA pilot study of temsirolimus and body composition
Rodrigues, H. V., Parsons, H. A., Jankú, F., Naing, A., Wheler, J. J., Tsimberidou, A. M., & Kurzrock, R. (2013) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-013-0113-y · Cited by 30
“of adipose cells, impairing lipid deposition on adipose tissue and culminating in elevated plasma levels of triglycerides [16].”
Emerging therapeutic approaches in the management of retinal angiogenesis and edema
Truong, A., Wong, T. Y., & Khachigian, L. M. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0709-z · Cited by 30
“In organ transplant recipients taking high-dose rapamycin, hyperglycemia and hyperlipidemia may develop [139, 140].”
BackgroundDas, F., Ghosh‐Choudhury, N., Venkatesan, B. A., Kasinath, B. S., & Choudhury, G. G. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00666.2016 · Cited by 28
Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging
Mau, T., O’Brien, M., Ghosh, A. K., Miller, R. A., & Yung, R. L. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz177 · Cited by 30
The Challenges of Treating Patients with Breast Cancer and Obesity
LeVee, A. A., & Mortimer, J. E. (2023) · Cancers · doi:10.3390/cancers15092526 · Cited by 30
Comparison of rapamycin schedules in mice on high-fat diet
Leontieva, O. V., Paszkiewicz, G., & Blagosklonny, M. V. (2014) · Cell Cycle · doi:10.4161/15384101.2014.970491 · Cited by 27
“It was shown that rapamycin decreases obesity in rodents and humans.(33-41) If used properly, this “immunosuppressant” can stimulate immunity.”
BackgroundLasram, M. M., El-Golli, N., Jrad-Lamine, A., Douib, I. B., Bouzid, K., Annabi, A. B., Fazâa, S. E., Abdelmoula, J., & Gharbi, N. (2014) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2014.10.002 · Cited by 28
Hughes, K. J., & Kennedy, B. K. (2012) · Science · doi:10.1126/science.1221365 · Cited by 26
Zhao, Z., Deng, X., Jia, J., Zhao, L., Wang, C., Cai, Z., Guo, C. Y., Yang, L., Wang, D., Ma, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154921 · Cited by 26
Józefczuk, J., Kashofer, K., Ummanni, R., Henjes, F., Rehman, S., Geenen, S., Wruck, W., Regenbrecht, C. R. A., Daskalaki, A., Wierling, C., et al. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00339 · Cited by 30
Waise, T. M. Z., Rasti, M., Duca, F. A., Zhang, S., Bauer, P. V., Rhodes, C. J., & Lam, T. K. T. (2019) · Nature Communications · doi:10.1038/s41467-019-08582-7 · Cited by 26
Intestinal Dysbiosis Correlates With Sirolimus-induced Metabolic Disorders in Mice
Han, Y., Wu, L. M., Ling, Q., Wu, P., Zhang, C., Jia, L., Weng, H., & Wang, B. (2020) · Transplantation · doi:10.1097/tp.0000000000003494 · Cited by 31
mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Saha, S., Fang, X., Green, C. D., & Das, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015078 · Cited by 26
“Rapamycin, another direct mTORC1 inhibitor, has been closely linked to improved T2D and diabetic cardiac dysfunction [75–77], but multiple studies have reported controversial effects of chronic treatment with rapamycin [78,79].”
BackgroundGeroprotector drugs and exercise: friends or foes on healthy longevity?
Elliehausen, C. J., Anderson, R. M., Diffee, G. M., Rhoads, T. W., Lamming, D. W., Hornberger, T. A., & Konopka, A. R. (2023) · BMC Biology · doi:10.1186/s12915-023-01779-9 · Cited by 27
Lopes, P. C. M. M., Fuhrmann, A., Sereno, J., Espinoza, D., Pereira, M. J., Eriksson, J. W., Reis, F., & Carvalho, E. (2014) · Metabolism · doi:10.1016/j.metabol.2014.02.004 · Cited by 24
“[32].”
BackgroundPosttransplant Metabolic Syndrome
Siddiqui, M. S., & Sterling, R. K. (2012) · International Journal of Hepatology · doi:10.1155/2012/891516 · Cited by 25
“Chronic mTOR inhibition has been associated with reduced pancreatic β-cell mass, reduced hepatic insulin clearance, and increased gluconeogenesis, thereby causing insulin resistance [29].”
Lin, X., Shi, H., Cui, Y., Wang, X., Zhang, J., Yu, W., & Wei, M. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6194 · Cited by 26
“Phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) are important rate-limiting enzymes that regulate hepatic gluconeogenesis (10).”
Granata, S., Mercuri, S., Troise, D. E., Gesualdo, L., Stallone, G., & Zaza, G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1168967 · Cited by 23
“Reduced obesity and hyperlipidemia are frequently associated with the mTOR-I treatment (58, 60).”
BackgroundInfluentialThe Combined Deletion of S6K1 and Akt2 Deteriorates Glycemic Control in a High-Fat Diet
Treins, C., Alliouachene, S., Hassouna, R., Xie, Y., Birnbaum, M. J., & Pende, M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00514-12 · Cited by 23
“In agreement with our findings, there is increasing evidence in animal models and in humans suggesting that chronic administration of the mTOR inhibitor rapamycin has deleterious effects on glucose homeostasis, possibly due to a combined deterioration of insulin sensitivity and insulin secretion (10, 15, 17, 37, 38).”
ResultAntonuzzo, L., Re, M. D., Barucca, V., Spada, F., Meoni, G., Restante, G., Danesi, R., Costanzo, F. D., & Fazio, N. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.001 · Cited by 23
Dissecting Mammalian Target of Rapamycin to Promote Longevity
Mendelsohn, A. R., & Larrick, J. W. (2012) · Rejuvenation Research · doi:10.1089/rej.2012.1347 · Cited by 23
Shum, M., Houde, V. P., Bellemare, V., Moreira, R. J., Bellmann, K., St‐Pierre, P., Viollet, B., Foretz, M., & Marette, A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008488 · Cited by 24
“Western blots were performed as described previously (36).”
MethodSelf-citationTargeting mTOR in the Context of Diet and Whole-body Metabolism
Koundouros, N., & Blenis, J. (2022) · Endocrinology · doi:10.1210/endocr/bqac041 · Cited by 24
Regulation of adiposity by mTORC1
Magdalon, J., & Festuccia, W. T. (2017) · Einstein (São Paulo) · doi:10.1590/s1679-45082017rb4106 · Cited by 23
Self-citationYang, P., Zhao, Y., Zhao, L., Yuan, J., Chen, Y., Varghese, Z., Moorhead, J. F., Chen, Y., & Ruan, X. Z. (2015) · Scientific Reports · doi:10.1038/srep14959 · Cited by 21
mTOR Signaling Pathway in Bone Diseases Associated with Hyperglycemia
Wang, S., Wang, J., Wang, S., Tao, R., Yi, J., Chen, M., & Zhao, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119198 · Cited by 22
“For glucose metabolism, rapamycin administration is effective in promoting insulin secretion and glucose uptake in the short term [158], but chronic treatment may exacerbate hyperglycemia and insulin resistance [159].”
BackgroundCaron, A., Baraboi, E., Laplante, M., & Richard, D. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23668 · Cited by 22
“Unfortunately, chronic treatment of rodents with rapamycin induces several side effects including a reduction in b-cell mass/function, hyperlipidemia, glucose intolerance, and severe insulin resistance (Aggarwal et al., 2006; Fraenkel et al., 2008; Houde et al., 2010).”
BackgroundEdick, A. M., Auclair, O., & Burgos, S. A. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00025.2019 · Cited by 22
“Moreover, chronic rapamycin treatment in rats and mice causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue (19, 23), possibly through disruption of the mTORC2 complex (23).”
BackgroundAndrade, M. L., Gilio, G. R., Perandini, L. A., Peixoto, Á. S., Moreno, M. F., Castro, É., Oliveira, T. E., Vieira, T. S., Ortiz‐Silva, M., Thomazelli, C. A., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158967 · Cited by 30
Self-citationFok, W. C., Livi, C. B., Bokov, A. F., Yu, Z., Chen, Y., Richardson, A. G., & Pérez, V. (2014) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2014.07.004 · Cited by 22
“In addition, 15 days of rapamycin injection in Sprague-Dawley rats reduces adiposity, decrease fat cell numbers, and down-regulate genes involved in lipid uptake, and storage (Houde et al., 2010).”
BackgroundSamidurai, A., Salloum, F. N., Durrant, D., Chernova, O. B., Kukreja, R. C., & Das, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14059 · Cited by 21
“Relatively high dose of chronic rapamycin treatment (~2mg·kg 1·day 1 for 14 days) impairs whole-body insulin sensitivity by disrupting the integrity of mTORC2 in normal mice and rats (Houde et al., 2010; Lamming et al., 2012).”
BackgroundCardioprotective effects of dietary rapamycin on adult female C57BLKS/J‐Leprdb mice
Reifsnyder, P. C., Ryzhov, S. V., Flurkey, K., Anunciado‐Koza, R. P., Mills, I., Harrison, D. E., & Koza, R. A. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13557 · Cited by 21
Choi, D. H., Yang, J., & Kim, Y. (2019) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2018.12.009 · Cited by 24
“Studies have shown that chronic administration of RAP suppresses the phosphorylation of p70S6K in rat skeletal muscles [30,31], murine cardiac muscle [34], and murine liver [32].”
Gene program-specific regulation of PGC-1α activity
Schmidt, S. F., & Mandrup, S. (2011) · Genes & Development · doi:10.1101/gad.2076411 · Cited by 24
“Consistent with an important role of S6K1 in repressing the hepatic fasting gene program, inhibition of mTOR by rapamycin has been shown to induce gluconeogenic gene expression and cause insulin resistance and glucose intolerance in mice (Houde et al. 2010).”
BackgroundSide Effects of Immunosuppressant Drugs After Liver Transplant
Gabrielli, F., Bernasconi, E., Toscano, A., Avossa, A., Cavicchioli, A., Andreoné, P., & Gitto, S. (2025) · Pharmaceuticals · doi:10.3390/ph18030342 · Cited by 22
“These effects are primarily attributed to a reduction in β -cell mass, decreased hepatic insulin clearance, and increased hepatic gluconeogenesis, all of which are induced by direct mTOR-I [129].”
Ancu, O., Mickute, M., Guess, N. D., Hurren, N. M., Burd, N. A., & Mackenzie, R. W. (2020) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2020-0396 · Cited by 23
“While amino acids are potent activators of mTORC1, some suggest that amino acid associated activation of mTOR may not be sufficient to induce insulin resistance (Houde et al. 2010; Li et al. 2013).”
BackgroundCarter, C. S., Khamiss, D., Matheny, M. E., Toklu, H. Z., Kirichenko, N., Strehler, K. Y. E., Tümer, N., Scarpace, P. J., & Morgan, D. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu238 · Cited by 20
“Unfortunately, there is some indication that rapamycin treatment may actually be detrimental to health in older animals due to its aberrant effects on glucose and/ or insulin signaling (8,9) as well as a potential for exacerbating agerelated, down-regulated mTOR function in rat skeletal muscle (10).”
BackgroundGarcía-Casarrubios, E., de Moura, C., Arroba, A. I., Pescador, N., Calderón‐Domínguez, M., Garcia, L., Herrero, L., Serra, D., Cadenas, S., Reis, F., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.09.016 · Cited by 21
Rapamycin impairs HPD ‐induced beneficial effects on glucose homeostasis
Chang, G., Chiu, Y., Wu, Y., Lin, Y., Hou, P., & Mao, F. C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13168 · Cited by 19
“In addition, we found increased serum insulin levels in rapamycin-treated mice, which is consistent with defects in hepatic insulin clearance (Houde et al., 2010).”
BackgroundYan, X., Pan, Y.-H., Fan, R., Song, Q., Li, S., Huang, J.-L., Li, W., Huang, D., Yuan, F.-Y., Tang, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00067 · Cited by 19
Targeting a mTOR/autophagy axis: a double-edged sword of rapamycin in spontaneous miscarriage
Li, M., Shen, H.-H., Cao, X.-Y., Gao, X.-X., Xu, F.-Y., Ha, S., Sun, J., Liu, S., Xie, F., & Li, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116976 · Cited by 23
Haller, M., Amatschek, S., Wilflingseder, J., Kainz, A., Bielesz, B. O., Pavik, I., Serra, A. L., Mohebbi, N., Biber, J., Wagner, C. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039229 · Cited by 19
Daumone fed late in life improves survival and reduces hepatic inflammation and fibrosis in mice
Park, J. H., Chung, H. Y., Kim, M., Lee, J. H., Jung, M., & Ha, H. (2014) · Aging Cell · doi:10.1111/acel.12224 · Cited by 19
Das, F., Ghosh‐Choudhury, N., Mariappan, M. M., Kasinath, B. S., & Choudhury, G. G. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00266.2015 · Cited by 19
“Chronic use of rapamycin, which blocks both mTORC1 and mTORC2, produces glucose intolerance, insulin resistance, and new-onset diabetes in both rodents and humans (21, 26, 30, 51, 72).”
Nakamura, M., Satoh, N., Horita, S., & Nangaku, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015204 · Cited by 20
“These changes were observed despite normal activation of the IRS/PI3k/Akt pathway in the liver of rapamycin-treated rats (Houde et al., 2010).”
BackgroundAsayama, M., Yamada-Murano, T., Hara, H., Ooki, A., Kurosumi, M., & Yamaguchi, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt193 · Cited by 20
Saha, N., Jyrwa, L. M., Das, M. K., & Biswas, K. (2011) · Fish Physiology and Biochemistry · doi:10.1007/s10695-011-9468-1 · Cited by 20
Uchinaka, A., Yoneda, M., Yamada, Y., Murohara, T., & Nagata, K. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.331 · Cited by 21
“Chronic rapamycin treatment aggravates glucose metabolism in diabetic subjects (Houde et al. 2010; Lamming et al. 2012).”
BackgroundResultInteractions of the super complexes: When mTORC1 meets the proteasome
Adegoke, O. A. J., Beatty, B., Kimball, S. R., & Wing, S. S. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105638 · Cited by 19
Santiago, J., Boylan, J. M., Lemieux, F. A., Gruppuso, P. A., Sanders, J. A., & Rand, D. M. (2021) · BMC Genomics · doi:10.1186/s12864-021-07516-2 · Cited by 29
Ehinger, Y., Zhang, Z., Phamluong, K., Soneja, D., Shokat, K. M., & Dorit Ron, A. (2021) · Nature Communications · doi:10.1038/s41467-021-24567-x · Cited by 18
Caerulomycin A Suppresses Immunity by Inhibiting T Cell Activity
Singla, A. K., Gurram, R. K., Chauhan, A., Khatri, N., Vohra, R. M., Jolly, R. S., & Agrewala, J. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107051 · Cited by 18
“Recent studies revealed that these drugs have severe side-effects during long-term clinical applications [9,10].”
BackgroundA mixed blessing for liver transplantation patients — Rapamycin
Fan, G.-H., Zhang, C.-Z., Gao, F., Wei, X., Ling, S., Wang, K., Wang, J., Zheng, S., Nikfarjam, M., & Xu, X. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.10.004 · Cited by 19
Umeki, D., Ohnuki, Y., Mototani, Y., Shiozawa, K., Fujita, T., Nakamura, Y., Saeki, Y., & Okumura, S. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12195fp · Cited by 18
Evaluation of the Impact of the Cancer Therapy Everolimus on the Central Nervous System in Mice
Dubois, M., Joncour, V. L., Tonon, M., Anouar, Y., Proust, F., Morin, F., Gandolfo, P., Joly, F., Hilber, P., & Castel, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113533 · Cited by 18
“As mTOR signaling pathway plays an important role in homeostasis in visceral organs and brain [2, 60], weight loss described after everolimus treatment could be associated with a skeletal muscle atrophy caused by a protein synthesis alteration in muscles [58] and/or inhibition of fat accumulation [61], but also with t…”
BackgroundBarnett, B. G., Wesselowski, S. R., Gordon, S. G., Saunders, A. B., Promislow, D., Schwartz, S. M., Chou, L., Evans, J. B., Kaeberlein, M. R., & Creevy, K. E. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1168711 · Cited by 17
“At dosages intended to mitigate age-related changes, adverse events associated with rapamycin are uncommon in rodents, and include hyperlipidemia, gonadal atrophy, and cataract formation, as well as altered glucose homeostasis with chronic use (19, 38).”
BackgroundKiani, P., Khodadadi, E. S., Nikdasti, A., Yarahmadi, S., Gheibi, M., Yousefi, Z., Ehtiati, S., Yahyazadeh, S., Shafiee, S. M., Taghizadeh, M., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05207-0 · Cited by 19
“Chang and Houde also showed that treatment of mice with Rapamycin leads to glucose intolerance, increased insulin resistance and fat accumulation inside the cells [189, 190].”
Obesity, overweight and breast cancer: new clinical data and implications for practice
García‐Estévez, L., González-Rodríguez, M., Calvo, I., Orta, A., Gión, M., Moreno‐Bueno, G., Pérez-García, J. M., & Cortés, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1579876 · Cited by 19
NEAT1/hsa-miR-372–3p axis participates in rapamycin-induced lipid metabolic disorder
Fan, G., Zhang, C., Wei, X., Wei, R., Qi, Z., Chen, K., Cai, X., Xu, L., Tang, L., Zhou, J., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.033 · Cited by 26
Ge, C., Ma, C., Cui, J., Dong, X., Sun, L., Li, Y., & Yu, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281888 · Cited by 18
An, J. H., Cho, D. H., Lee, G. Y., Kang, M. S., Kim, S. J., & Han, S. N. (2021) · Nutrients · doi:10.3390/nu13030796 · Cited by 17
Lawendy, B., Srinathan, S., Kotha, S., Gomes, C., Misra, S., Yu, J., Orchanian‐Cheff, A., TOMLINSON, G. A., & Bhat, M. (2021) · Clinical Transplantation · doi:10.1111/ctr.14340 · Cited by 19
Obesity under the moonlight of c-MYC
Nevzorova, Y. A., & Cubero, F. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1293218 · Cited by 16
Chen, Y., Lai, M.-H., Hsin-Yu, H. U. N. G., & Liu, J. (2013) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.59.272 · Cited by 16
Wu, Q., Liu, J., Liu, L., Chen, Y., Wang, J., Leng, L., Yu, Q., Duan, Z., & Wang, Y. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00652 · Cited by 16
Duval, N., Vacano, G. N., & Patterson, D. W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00263 · Cited by 16
Possible New Strategies for the Treatment of Congenital Hyperinsulinism
Sikimic, J., Hoffmeister, T., Gresch, A., Kaiser, J., Barthlen, W., Wolke, C., Wieland, I., Lendeckel, U., Krippeit‐Drews, P., Düfer, M., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.545638 · Cited by 17
“Furthermore, upregulation of liver gluconeogenesis by sirolimus contributes to insulin resistance (114).”
BackgroundShinagawa, F. B., de Santana, F. C., & Mancini-Filho, J. (2015) · Revista de Nutrição · doi:10.1590/1415-52732015000100006 · Cited by 21
mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions
Fernandes-Silva, G., de Paula, M. I., & Rangel, É. B. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1239708 · Cited by 18
“dyslipidemia mainly by reducing adipose tissue lipid uptake and deposition, likely through inhibition of lipoprotein lipase and PPAR-γ activities [135].”
BackgroundThe clinical course and potential underlying mechanisms of everolimus-induced hyperglycemia
Tanimura, J., Nakagawa, H., Tanaka, T., Kikuchi, A., Osada, S., Tanaka, Y., Tokuyama, K., & Takamura, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0542 · Cited by 16
Wang, D., Yang, L., Ding, W., Chen, Z., Yang, X., Jiang, Y., & Liu, Y. (2023) · Phytotherapy Research · doi:10.1002/ptr.8044 · Cited by 16
“These effects of LCA on insulin sensitivity are likely to be mediated by its inhibitory action on mTORC1. mTORC1 negatively regulates insulin signaling through a (p70S6) S6K-dependent feedback loop that reduces the coupling of insulin receptors with its downstream effectors (Houde et al., 2010).”
BackgroundLopes, P. C. M. M., Fuhrmann, A., de Carvalho, F. J. N., Sereno, J., Santos, M. R., Pereira, M. J., Eriksson, J. W., Reis, F., & Carvalho, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.014 · Cited by 16
“However, no differences were found in glycogen content in the liver between the treated groups, in agreement with Houde and Brûlé [26] and Pfaffenbach and Nivala [36].”
BackgroundResultLopes, P., Fuhrmann, A., Sereno, J., Pereira, M. J., Nunes, P. M., Pedro, J., Melão, A., Reis, F., & Carvalho, E. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.02.009 · Cited by 15
Rapamycin up-regulates triglycerides in hepatocytes by down-regulating Prox1
Kwon, S., Jeon, J.-S., Kim, S. B., Hong, Y., Ahn, C., Sung, J., & Choi, I. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0211-x · Cited by 15
“Recent studies have reported that rapamycin can inhibit the transactivation of several transcription factors such as peroxisome proliferator-associated receptor-gamma (PPARγ) and CCAAT-enhancer-binding proteins (C/EBP), which play key roles in lipid metabolism [22] and it can change the expression of key enzymes requi…”
BackgroundSirolimus in the treatment of three infants with diffuse congenital hyperinsulinism
Albalwi, R. A., Alatawi, M. S., Alotaibi, A., Babiker, O., & Almutair, A. (2017) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0229 · Cited by 15
Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats
Wu, K., Huang, H., Chang, T. T., Lee, W.-S., Chuang, C., Hsin, I., Hsu, S., Lee, F., Chang, C.-C., & Lee, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.016 · Cited by 15
Tangseefa, P., Martin, S. K., Chin, P. Y., Breen, J., Mah, C. Y., Baldock, P. A. J., Wittert, G., Page, A. J., Proud, C. G., Fitter, S., et al. (2021) · Bone Research · doi:10.1038/s41413-020-00123-z · Cited by 17
Rodent diet aids and the fallacy of caloric restriction
Wolf, A. M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111584 · Cited by 16
“ciency and decreased plasma leptin levels (Houde et al., 2010).”
Hyperlipidaemia in immunosuppression
Kockx, M., & Kritharides, L. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000363 · Cited by 16
“inhibition of mTOR complex 1 decreases LPL activity and inhibits adipose lipid storage [14,15].”
BackgroundIntermittent mTOR Inhibition Reverses Kidney Aging in Old Rats
Francesco, A. D., Díaz‐Ruiz, A., de Cabo, R., & Bernier, M. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly023 · Cited by 16
Ju, Y., Edman, M. C., Guo, H., Janga, S. R., Peddi, S., Louie, S. G., Junge, J. A., MacKay, J. A., & Hamm‐Alvarez, S. F. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c01468 · Cited by 14
Dietary Restriction and Lipid Metabolism: Unveiling Pathways to Extended Healthspan
Lee, H., & Min, K. (2024) · Nutrients · doi:10.3390/nu16244424 · Cited by 15
Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review
Karvelas, G., Roumpi, A., Komporozos, C., & Syrigos, K. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.01.013 · Cited by 14
Kell, L., Jones, E. J., Gharahdaghi, N., Wilkinson, D. J., Smith, K., Atherton, P. J., Simon, A. K., Cox, L. S., & Alsaleh, G. (2026) · Aging Cell · doi:10.1111/acel.70364 · Cited by 17
“At high doses, rapamycin is immunosuppressive and causes side effects such as poor wound healing, ulcers, and loss of metabolic control leading to diabetes (Knight et al. 2007; Altomare et al. 2006; Houde et al. 2010).”
Calorie restriction mimetics against aging and inflammation
Chaudhary, S., Chaudhary, M. R., Jena, M. K., Rath, P. K., Mishra, B. P., Paital, B., Vyas, A., Sahoo, D. K., Singh, P., & Mehdi, M. M. (2025) · Biogerontology · doi:10.1007/s10522-025-10269-0 · Cited by 15
Sangüesa, G., Montañés, J. C., Baena, M., Sánchez, R. M., Roglans, N., Alegret, M., & Laguna, J. C. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1654-9 · Cited by 15
Adverse Effects of Immunosuppression: Nephrotoxicity, Hypertension, and Metabolic Disease
Hoosain, J., & Hamad, E. A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_547 · Cited by 14
Sam, W. J., Chamberlain, C. E., Lee, S., Goldstein, J. A., Hale, D. A., Mannon, R. B., Kirk, A. D., & Hon, Y. Y. (2012) · Transplantation · doi:10.1097/tp.0b013e31826b55e2 · Cited by 14
“In addition, messenger RNA expression of several genes that are involved in lipid uptake and storage was decreased in adipose tissue of rats receiving chronic SRL treatment (8).”
BackgroundExpert opinion on the metabolic complications of mTOR inhibitors
Bouillet, B., Buffier, P., Smati, S., Archambeaud, F., Cariou, B., & Vergès, B. L. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.010 · Cited by 14
Metadata
- Authors
- Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Corresponding author
- Marette, André
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-03-18
- Volume
- 59
- Issue
- 6
- Pages
- 1338-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2874694
- OpenAlex
- W2153442288
- Cited by
- 456
- References
- 51
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 14 · 2023: 25 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 26 · 2018: 33 · 2017: 37 · 2016: 35 · 2015: 42 · 2014: 47 · 2013: 32 · 2012: 30
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval
- Canadian Institutes of Health Research (144336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- hepatic gluconeogenesis, impaired glucose tolerance, hyperlipidemia, insulin resistance, PGC-1α, FOXO1, CRTC2, CREB, PI3K/Akt signaling, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, adiposity
- MeSH terms
- Adipose Tissue, Animals, Blood Glucose, C-Peptide, Fatty Acids, Nonesterified, Glucagon, Hyperlipidemias, Immunosuppressive Agents, Insulin, Liver, Male, Pyruvates, RNA, Triglycerides, Down-Regulation, Polymerase Chain Reaction, Rats, Sprague-Dawley, Adipocytes, Glucose Intolerance, Muscle, Skeletal, Sirolimus, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.